Guest Editorial

REFERENCES

• Cheng, P., Corzo, C. A., Luetteke, N., Yu, B., Nagaraj, S., Bui, M. M., Ortiz, M., Nacken, W., Sorg, C., Vogl, T., (2008). Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 205: 2235–2249.
   PubMed Web of Science ®Google Scholar
• Cohen, P. A., Ko, J. S., Storkus, W. J., Spencer, C. D., Bradley, J. M., Gorman, J. E., McCurry, D. B., Zorro-Manrique, S., Dominguez, A. L., Pathangey, L. B., (2012). Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape. Immunol Invest, this issue.
   Google Scholar
• Gabrilovich, D. I., Ostrand-Rosenberg, S., Bronte, V. (2012). Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12: 253–268.
   PubMed Web of Science ®Google Scholar
• Haile, L., Greten, T., and Korangy, F. (2012). Immune suppression: the hallmark of myeloid-derived suppressor cells. Immunol Invest, this issue.
   Google Scholar
• Harden, J., Egilmez, N. (2012). Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity. Immunol Invest, this issue.
   Google Scholar
• Johnson, T., Munn, D. H. (2012). Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance. Immunol Invest, this issue.
   Google Scholar
• Kohanbash, G., Okada, H. (2012). Myeloid-derived suppressor Cells (MDSCs) in gliomas and glioma-development. Immunol Invest, this issue.
   Google Scholar
• Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., Fearon, D. T. (2010). Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330: 827–830.
   PubMed Web of Science ®Google Scholar
• Luo, Y., Zhou, H., Krueger, J., Kaplan, C., Lee, S. H., Dolman, C., Markowitz, D., Wu, W., Liu, C., Reisfeld, R. A., Xiang, R. (2006). Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest 116:2132–2141.
   PubMed Web of Science ®Google Scholar
• Manjili, M. H. (2012). Phenotypic plasticity of MDSC in cancers. Immunol Invest, this issue.
   Google Scholar
• Monu, N. R., Frey, A. B. (2012). Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship. Immunol Invest, this issue.
   Google Scholar
• Munn, D. H., Sharma, M. D., Lee, J. R., Jhaver, K. G., Johnson, T. S., Keskin, D. B., Marshall, B., Chandler, P., Antonia, S. J., Burgess, R., (2002). Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297:1867–1870.
   PubMed Web of Science ®Google Scholar
• Obermajer, N., Wong, J. L., Edwards, R. P., Odunsi, K., Moysich, K., Kalinski, P. (2012). PGE2-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells. Immunol Invest, this issue.
   Google Scholar
• Qu, P., Boelte, K. C., Lin, P. C. (2012). Negative regulation of myeloid-derived suppressor cells in cancer. Immunol Invest, this issue.
   Google Scholar
• Raber, P., Ochoa, A., Rodriguez, P. (2012). Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest, this issue.
   Google Scholar
• Rosenbauer, F., Tenen, D. G. (2007). Transcription factors in myeloid development: balancing differentiation with transformation. Nat Rev Immunol 7:105–117.
   PubMed Web of Science ®Google Scholar
• Sawanobori, Y., Ueha, S., Kurachi, M., Shimaoka, T., Talmadge, J. E., Abe, J., Shono, Y., Kitabatake, M., Kakimi, K., Mukaida, N., Matsushima, K. (2008). Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 111:5457–5466.
   Google Scholar
• Sica, A., Mantovani, A. (2012). Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122:787–795.
   PubMed Web of Science ®Google Scholar
• Sinha, P., Okoro, C., Foell, D., Freeze, H. H., Ostrand-Rosenberg, S., Srikrishna, G. (2008). Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 181:4666–4675.
   PubMed Web of Science ®Google Scholar
• Solito, S., Pinton, L., Damuzzo, V., Mandruzzato, S. (2012). Highlights on molecular mechanisms of MDSC-mediated immune suppression: paving the way for new working hypotheses. Immunol Invest, this issue.
   Google Scholar
• Stewart, T. J., Greeneltch, K. M., Reid, J. E., Liewehr, D. J., Steinberg, S. M., Liu, K., Abrams, S. I. (2009a). Interferon regulatory factor-8 modulates the development of tumour-induced CD11b+Gr-1+ myeloid cells. J Cell Mol Med 13:3939–3950.
   PubMed Web of Science ®Google Scholar
• Stewart, T. J., Liewehr, D. J., Steinberg, S. M., Greeneltch, K. M., Abrams, S. I. (2009b). Modulating the expression of IFN regulatory factor 8 alters the protumorigenic behavior of CD11b+Gr-1+ myeloid cells. J Immunol 183:117–128.
   Google Scholar
• Tadmor, T., Attias, D., Polliack, A. (2011). Myeloid-derived suppressor cells–their role in haemato-oncological malignancies and other cancers and possible implications for therapy. Br J Haematol 153:557–567.
   PubMed Web of Science ®Google Scholar
• Waight, J. D., Hu, Q., Miller, A., Liu, S., Abrams, S. I. (2011). Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS One 6: e27690.
   PubMed Web of Science ®Google Scholar